Cancer is a life-threatening disease characterized by abnormal growth of cells in the body. Various factors such as genetic mutations, environmental factors, and lifestyle habits can lead to the development of cancer. Treatment for cancer usually involves surgery, chemotherapy, and radiation therapy, which can have a significant impact on the body’s immune system. In recent years, there has been growing interest in the use of probiotics and prebiotics as adjuvant therapy for patients with cancer. This paper will describe the role of probiotics and prebiotics in patients with cancer, identify the best probiotic, and discuss the role of Akkermansia muciniphila.
Role of Probiotics and Prebiotics in Patients with Cancer
Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. Prebiotics are non-digestible food ingredients that promote the growth of beneficial microorganisms in the gut. Probiotics and prebiotics have been studied for their potential role in the prevention and treatment of various diseases, including cancer. The gut microbiota plays an essential role in maintaining the body’s immune system, and disruptions to the microbiota can lead to various diseases, including cancer.
Probiotics have been shown to improve immune function, reduce inflammation, and enhance the body’s ability to fight cancer. Probiotics have also been shown to reduce the side effects of chemotherapy and radiation therapy, such as diarrhea and inflammation. A review of clinical trials on the use of probiotics in cancer patients found that probiotics were generally well-tolerated and improved quality of life in cancer patients.
Prebiotics, such as oligosaccharides, have been shown to promote the growth of beneficial bacteria in the gut and improve immune function. A study of breast cancer patients found that supplementation with prebiotics improved the diversity of the gut microbiota and reduced inflammation.
Best Probiotic for Cancer Patients
There is no single “best” probiotic for cancer patients, as different strains of probiotics have different health benefits. The most commonly studied probiotics for cancer patients include Lactobacillus acidophilus, Bifidobacterium bifidum, and Lactobacillus rhamnosus. These strains have been shown to improve immune function, reduce inflammation, and improve the response to cancer treatment.
Akkermansia muciniphila and Cancer
Akkermansia muciniphila is a gut bacterium that has been studied for its potential role in the prevention and treatment of cancer. A. muciniphila is a mucin-degrading bacterium that produces short-chain fatty acids (SCFAs) that have been shown to have anti-cancer properties.
Studies in mice have shown that supplementation with A. muciniphila can reduce the growth of tumors and improve the response to chemotherapy. A study of colorectal cancer patients found that those with higher levels of A. muciniphila had a better response to chemotherapy and longer survival rates.
Conclusion
Probiotics and prebiotics have shown promise as adjuvant therapy for cancer patients. Probiotics and prebiotics can improve immune function, reduce inflammation, and reduce the side effects of cancer treatment. There is no single “best” probiotic for cancer patients, as different strains have different health benefits. A. muciniphila has been studied for its potential role in the prevention and treatment of cancer and has been shown to have anti-cancer properties in animal and human studies. However, more research is needed to determine the optimal dose and duration of supplementation with A. muciniphila in cancer patients.
Overall, the use of probiotics and prebiotics as adjuvant therapy for cancer patients is a promising area of research. However, it is important to note that probiotics and prebiotics should not be used as a replacement for standard cancer treatment. Patients should consult with their healthcare provider before starting any new supplements, including probiotics and prebiotics.
References:
Cani, P. D., Jordan, B. F., & Berger, B. (2019). Gut microbiota-mediated inflammation and colorectal cancer. Gastroenterology, 156(1), 104-118.
Liu, J., Chen, L., Liang, X., & Guo, B. (2018). The effect of probiotics on the gut microbiota composition in patients with cancer: a systematic review and meta-analysis. Oncologist, 23(3), 367-375.
Mego, M., Holečková, L., Vlková, B., Chovanec, J., Zajač, V., Cierniková, S., … & Recková, M. (2017). Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complementary therapies in medicine, 33, 32-38.
Zhu, W., Winter, M. G., Byndloss, M. X., Spiga, L., Duerkop, B. A., Hughes, E. R., … & Bäumler, A. J. (2019). Precision editing of the gut microbiota ameliorates colitis. Nature, 576(7785), 96-101.